Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026GlobeNewsWire • Monday
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAOGlobeNewsWire • 09/30/26
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal InjectionsGlobeNewsWire • 08/20/26
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye DiseaseGlobeNewsWire • 08/06/26
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026GlobeNewsWire • 07/27/26
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026GlobeNewsWire • 07/20/26
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual MeetingGlobeNewsWire • 07/20/26
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with HarrowBusiness Wire • 07/01/26
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the USZacks Investment Research • 06/11/26
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric EyecareGlobeNewsWire • 06/10/26
HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law ViolationsGlobeNewsWire • 05/13/26